Investor Presentation Q1-Q3 2020
36
Investor presentation First nine months of 2020
Global diabetes prevalence is increasing and 700 million people
are expected to have diabetes by 2045.
Million
800
The number of people with diabetes is expected to
increase 51% by 2045
+51%
Of the 463 million, around 30 million people are currently treated
with Novo Nordisk diabetes products
700
579
600
J
500
463
400
300
200
100
0
700
2019
2030
2045
EMEA
Region China
ROW
North America
Novo NordiskⓇ
1.9 mio treated with GLP-1
2.4 mio treated with
new-generation insulin
13.0 mio treated with
modern insulin
10.9 mio treated with
human insulins
Source: International Diabetes Federation: Diabetes Atlas 1st Edition 2000 and Diabetes Atlas 9th Edition 2019
EMEA: Europe, Middle East, Africa; RoW: Asia Pacific, Latin America;
1 In addition to the above-mentioned product classes, oral anti-diabetics constitutes the remainder of people treated with Novo
Nordisk productsView entire presentation